For the quarter ending 2025-09-30, IRD had -$1,614K decrease in cash & cash equivalents over the period.
| Cash Flow | 2025-09-30 | 2025-06-30 |
|---|---|---|
| Net loss | -17,454 | -15,614 |
| Stock-based compensation | 816 | 1,809 |
| Depreciation | 13 | 27 |
| Fair value change in warrant and other derivative liabilities | -9,525 | 3,722 |
| Non-cash interest | 68 | - |
| Unrealized loss from short-term investments | 0 | -2 |
| Warrant financing costs | 0 | 1,337 |
| Accounts receivable | -483 | -164 |
| Contract assets and unbilled receivables | 186 | -1,031 |
| Prepaids and other current assets | -618 | 918 |
| Accounts payable | 906 | -1,703 |
| Accrued expenses | -946 | -1,676 |
| Net cash used in operating activities | -6,157 | -19,263 |
| Net cash used in investing activities | 0 | 0 |
| Proceeds from issuance of common stock and pre-funded warrants in connection with the march 2025 offering and march 2025 private placement | 0 | 5,980 |
| Proceeds from issuance of warrants in connection with the march 2025 offering and march 2025 private placement | 0 | 15,520 |
| Proceeds from issuance of common stock in connection with the at-the-market program, private placement and purchase agreement | 5,217 | 409 |
| Proceeds from funding agreement, related party | 0 | 1,000 |
| Issuance costs | 696 | 1,507 |
| Exercise of stock options | 22 | 5 |
| Share repurchases for the payment of employee taxes | 0 | 36 |
| Net cash provided by financing activities | 4,543 | 21,371 |
| Net increase (decrease) in cash and cash equivalents | -1,614 | 2,108 |
| Cash and cash equivalents at beginning of period | 30,321 | - |
| Cash and cash equivalents at end of period | 30,815 | - |
Opus Genetics, Inc. (IRD)
Opus Genetics, Inc. (IRD)